Shen Haifa, Mittal Vivek, Ferrari Mauro, Chang Jenny
Breast Cancer Res. 2013 May 8;15(3):205. doi: 10.1186/bcr3413.
The discovery of RNA interference has opened the door for the development of a new class of cancer therapeutics. Small inhibitory RNA oligos are being designed to specifically suppress expression of proteins that are traditionally considered nondruggable, and microRNAs are being evaluated to exert broad control of gene expression for inhibition of tumor growth. Since most naked molecules are not optimized for in vivo applications, the gene silencing agents need to be packaged into delivery vehicles in order to reach the target tissues as their destinations. Thus, the selection of the right delivery vehicles serves as a crucial step in the development of cancer therapeutics. The current review summarizes the status of gene silencing agents in breast cancer and recent development of candidate cancer drugs in clinical trials. Nanotechnology-based delivery vectors for the formulation and packaging of gene silencing agents are also described.
RNA干扰的发现为一类新型癌症治疗药物的开发打开了大门。人们正在设计小干扰RNA寡核苷酸以特异性抑制传统上被认为不可成药的蛋白质的表达，并且正在评估微小RNA以广泛控制基因表达来抑制肿瘤生长。由于大多数裸分子未针对体内应用进行优化，因此基因沉默剂需要包装到递送载体中才能到达靶组织。因此，选择合适的递送载体是癌症治疗药物开发中的关键步骤。本综述总结了乳腺癌中基因沉默剂的现状以及临床试验中候选癌症药物的最新进展。还描述了用于基因沉默剂制剂和包装的基于纳米技术的递送载体。
